西妥昔单抗和贝伐单抗在晚期结直肠癌一二线治疗中的研究进展

Research progress on Cetuximab and Bevacizumab in first and second-line treatment on advanced colorectal cancer

在我国,结直肠癌患者正呈现逐年上升的趋势,其治疗方法以手术为主,辅以放化疗,但效果却不甚理想。对于晚期结直肠癌的患者,已无法进行根治性手术切除,而放、化疗本身带来的毒副作用也严重影响患者的生活质量。近10年来,随着人们对西妥昔单抗和贝伐单抗等靶向药物的研究越来越深入,晚期结直肠癌患者再次迎来的新的曙光。在原有化疗药物的基础上使用靶向药物以进一步提高疗效也成为晚期结直肠癌一二线治疗新的发展趋势。此外,随着研究的不断深入,原发瘤部位的不同对靶向药物疗效的影响也成为医学界关注的焦点话题之一。本文就西妥昔单抗和贝伐单抗在晚期结直肠癌一二线治疗的研究进展以及左、右半结肠对靶向药物疗效的影响进行综述。

In China, the incidence of CRC is reportedly increasing over time. The treatment options including surgery,chemotherapy and radiotherapy, which are available depending mostly on disease stage. However, patients with advanced CRC have lost the chance of surgery,may also have a worse life because of chemotherapy and radiotherapy. With more and more studies on targeted therapy, such as Bevacizumab and Cetuximab, may shines a light for the patients with CRC.Chemotherapy combined with targeted therapy has become a new direction for the treatment of advanced CRC. Moreover, the association between tumor location and targeted therapy has become a hot topic. This review focuses on the progress of monoclonal antibody in the first-and second-tier treatment of advanced CRC and the effect of the left and right half colon on the efficacy of targeted drugs.